Literature DB >> 28240805

A multicenter study to define sarcopenia in patients with end-stage liver disease.

Elizabeth J Carey1, Jennifer C Lai2, Connie W Wang3, Srinivasan Dasarathy4, Iryna Lobach5, Aldo J Montano-Loza6, Michael A Dunn7.   

Abstract

Sarcopenia is associated with increased wait-list mortality, but a standard definition is lacking. In this retrospective study, we sought to determine the optimal definition of sarcopenia in end-stage liver disease (ESLD) patients awaiting liver transplantation (LT). Included were 396 patients newly listed for LT in 2012 at 5 North American transplant centers. All computed tomography scans were read by 2 individuals with interobserver correlation of 98%. Using image analysis software, the total cross-sectional area (cm2 ) of abdominal skeletal muscle at the third lumbar vertebra was measured. The skeletal muscle index (SMI), which normalizes muscle area to patient height, was then calculated. The primary outcome was wait-list mortality, defined as death on the waiting list or removal from the waiting list for reasons of clinical deterioration. Sex-specific potential cutoff values to define sarcopenia were determined with a grid search guided by log-rank test statistics. Optimal search methods identified potential cutoffs to detect survival differences between groups. The overall median SMI was 47.6 cm2 /m2 : 50.0 in men and 42.0 in women. At a median of 8.8 months follow-up, mortality was 25% in men and 36% in women. Patients who died had lower SMI than those who survived (45.6 versus 48.5 cm2 /m2 ; P < 0.001), and SMI was associated with wait-list mortality (hazard ratio, 0.95; P < 0.001). Optimal search method yielded SMI cutoffs of 50 cm2 /m2 for men and 39 cm2 /m2 for women; these cutoff values best combined statistical significance with a sufficient number of events to detect survival differences between groups. In conclusion, we recommend that an SMI < 50 cm2 /m2 for men and < 39 cm2 /m2 for women be used to define sarcopenia in patients with ESLD awaiting LT. Liver Transplantation 23 625-633 2017 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28240805      PMCID: PMC5762612          DOI: 10.1002/lt.24750

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  29 in total

1.  Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography.

Authors:  N Mitsiopoulos; R N Baumgartner; S B Heymsfield; W Lyons; D Gallagher; R Ross
Journal:  J Appl Physiol (1985)       Date:  1998-07

2.  Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.

Authors:  Puneeta Tandon; Michael Ney; Ivana Irwin; Mang M Ma; Leah Gramlich; Vincent G Bain; Nina Esfandiari; Vickie Baracos; Aldo J Montano-Loza; Robert P Myers
Journal:  Liver Transpl       Date:  2012-10       Impact factor: 5.799

3.  Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation.

Authors:  Cynthia Tsien; Ari Garber; Arvind Narayanan; Shetal N Shah; David Barnes; Bijan Eghtesad; John Fung; Arthur J McCullough; Srinivasan Dasarathy
Journal:  J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 4.029

4.  Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates.

Authors:  Anitha Yadav; Yu-Hui Chang; Sarah Carpenter; Alvin C Silva; Jorge Rakela; Bashar A Aqel; Thomas J Byrne; David D Douglas; Hugo E Vargas; Elizabeth J Carey
Journal:  Clin Transplant       Date:  2015-01-09       Impact factor: 2.863

5.  Muscle wasting is associated with mortality in patients with cirrhosis.

Authors:  Aldo J Montano-Loza; Judith Meza-Junco; Carla M M Prado; Jessica R Lieffers; Vickie E Baracos; Vincent G Bain; Michael B Sawyer
Journal:  Clin Gastroenterol Hepatol       Date:  2011-09-03       Impact factor: 11.382

6.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Authors:  Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

7.  Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma.

Authors:  Judith Meza-Junco; Aldo J Montano-Loza; Vickie E Baracos; Carla M M Prado; Vincent G Bain; Crystal Beaumont; Nina Esfandiari; Jessica R Lieffers; Michael B Sawyer
Journal:  J Clin Gastroenterol       Date:  2013 Nov-Dec       Impact factor: 3.062

Review 8.  Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation.

Authors:  J L A van Vugt; S Levolger; R W F de Bruin; J van Rosmalen; H J Metselaar; J N M IJzermans
Journal:  Am J Transplant       Date:  2016-04-04       Impact factor: 8.086

9.  Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.

Authors:  Aldo J Montano-Loza; Paul Angulo; Judith Meza-Junco; Carla M M Prado; Michael B Sawyer; Crystal Beaumont; Nina Esfandiari; Mang Ma; Vickie E Baracos
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-06-09       Impact factor: 12.910

10.  Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis.

Authors:  Aldo J Montano-Loza; Andres Duarte-Rojo; Judith Meza-Junco; Vickie E Baracos; Michael B Sawyer; Jack X Q Pang; Crystal Beaumont; Nina Esfandiari; Robert P Myers
Journal:  Clin Transl Gastroenterol       Date:  2015-07-16       Impact factor: 4.488

View more
  94 in total

1.  A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.

Authors:  Elizabeth J Carey; Jennifer C Lai; Christopher Sonnenday; Elliot B Tapper; Puneeta Tandon; Andres Duarte-Rojo; Michael A Dunn; Cynthia Tsien; Eric R Kallwitz; Vicky Ng; Srinivasan Dasarathy; Matthew Kappus; Mustafa R Bashir; Aldo J Montano-Loza
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

2.  Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Authors:  Rahima A Bhanji; Carlos Moctezuma-Velazquez; Andres Duarte-Rojo; Maryam Ebadi; Sunita Ghosh; Christopher Rose; Aldo J Montano-Loza
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

3.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 4.  The Impact of Frailty, Sarcopenia, and Malnutrition on Liver Transplant Outcomes.

Authors:  Nikki Duong; Brett Sadowski; Amol S Rangnekar
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

Review 5.  Nonalcoholic Steatohepatitis, Sarcopenia, and Liver Transplantation.

Authors:  Rahima A Bhanji; Yedidya Saiman; Kymberly D Watt
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 6.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

7.  Skeletal muscle loss phenotype in cirrhosis: A nationwide analysis of hospitalized patients.

Authors:  Adil Vural; Amy Attaway; Nicole Welch; Joe Zein; Srinivasan Dasarathy
Journal:  Clin Nutr       Date:  2020-04-03       Impact factor: 7.324

Review 8.  Reconsideration of frailty in relation to surgical indication.

Authors:  Kay Maeda; Yoshikatsu Saiki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-11-23

9.  Sarcopenia in a mice model of chronic liver disease: role of the ubiquitin-proteasome system and oxidative stress.

Authors:  Fabián Campos; Johanna Abrigo; Francisco Aguirre; Bruno Garcés; Marco Arrese; Saul Karpen; Daniel Cabrera; Marcelo E Andía; Felipe Simon; Claudio Cabello-Verrugio
Journal:  Pflugers Arch       Date:  2018-06-20       Impact factor: 3.657

Review 10.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.